Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 5.3% – Here’s What Happened

Posted by Brenda Bartman on Sep 11th, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report)’s share price dropped 5.3% during mid-day trading on Wednesday . The company traded as low as $8.96 and last traded at $8.93. Approximately 136,521 shares were traded during trading, a decline of 89% from the average session volume of 1,225,327 shares. The stock had previously closed at $9.43.

Analyst Ratings Changes

Several research firms have commented on PHAT. Craig Hallum reiterated a “buy” rating and set a $20.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, July 31st. Leerink Partners assumed coverage on shares of Phathom Pharmaceuticals in a report on Wednesday. They issued a “market perform” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a research report on Friday, July 31st. Barclays decreased their target price on shares of Phathom Pharmaceuticals from $18.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Finally, Needham & Company LLC dropped their price target on Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.25.

View Our Latest Research Report on PHAT

Phathom Pharmaceuticals Stock Down 3.5%

The company’s 50 day moving average price is $9.91 and its two-hundred day moving average price is $10.79. The firm has a market cap of $677.13 million, a PE ratio of -6.54 and a beta of 0.51.

Institutional Trading of Phathom Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in PHAT. Caitong International Asset Management Co. Ltd bought a new position in shares of Phathom Pharmaceuticals during the fourth quarter valued at approximately $27,000. Raymond James Financial Inc. bought a new stake in shares of Phathom Pharmaceuticals during the 2nd quarter worth approximately $30,000. Summit Securities Group LLC bought a new stake in shares of Phathom Pharmaceuticals during the 1st quarter worth approximately $34,000. Kestra Advisory Services LLC purchased a new position in Phathom Pharmaceuticals during the 4th quarter valued at $38,000. Finally, BNP Paribas Financial Markets boosted its holdings in Phathom Pharmaceuticals by 71.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock valued at $49,000 after acquiring an additional 2,122 shares during the period. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

(Get Free Report)

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.